Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ME-3183 by Meiji Seika Pharma for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
ME-3183 is under clinical development by Meiji Seika Pharma and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According...